BioGaia AB (BIOG.B) AI Stock Analysis

• Market Cap: kr10.77B
• Dividend Yield: 1.86%
• Average Volume (3M): 124.05K
• Price to Earnings (P/E): 37.0
• Beta (1Y): 0.35
• Revenue Growth: 7.88%
• EPS Growth: -6.35%
• Country: SE
• Employees: 224
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.87
• Shares Outstanding: 98,497,170
• 10 Day Avg. Volume: 90,103
• 30 Day Avg. Volume: 124,054
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 71 Outperform
• Price Target: kr115.00 ▲(9.32% Upside)

BioGaia AB's strong financial performance is the most significant factor, supported by solid profitability and a strong balance sheet. However, technical indicators suggest caution due to overbought conditions, and the high P/E ratio indicates a potentially expensive valuation. These factors combine to give a moderate overall stock score.

BioGaia AB Business Overview & Revenue Model

Company Description

BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through three segments: Pediatrics, Adult Health, and Other. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic and digestive health in children; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; general health; Helicobacter pylori–the gastric ulcer bacterium; and low bone density. It offers its products under the BioGaia brand name. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden.

How the Company Makes Money

BioGaia generates revenue primarily through the sale of its probiotic products, which include dietary supplements, functional foods, and medical devices. The company operates a business model that leverages both direct sales and partnerships with established distributors and retailers. Key revenue streams include sales to pharmacies, health food stores, and online platforms, as well as collaborations with healthcare professionals and institutions. Additionally, BioGaia engages in licensing agreements with third parties to utilize its proprietary strains of probiotics, which further diversifies its income. Strategic partnerships with global healthcare companies also play a significant role in expanding its product distribution and enhancing brand visibility, contributing positively to its overall earnings.

BioGaia AB Financial Statement Overview

Summary

BioGaia AB demonstrates strong financial performance with consistent revenue growth and healthy profit margins. The company maintains a robust equity ratio and no debt burden, indicating financial stability. However, slight declines in EBIT margin and free cash flow growth suggest minor operational challenges.

Income Statement

BioGaia AB has demonstrated strong financial performance with consistent revenue growth and healthy profit margins. The gross profit margin remained robust at 72.46% for 2024, reflecting efficient cost management. Net profit margin was similarly strong at 24.70%, indicating effective control over operating expenses. Revenue growth rate from 2023 to 2024 was 9.76%, showcasing positive upward trajectory. However, a slight decline in EBIT margin from 34.18% to 29.76% suggests potential challenges in operational efficiency.

Balance Sheet

The balance sheet of BioGaia AB is solid with a remarkable equity ratio of 84.77% for 2024, indicating financial stability and low reliance on debt. The debt-to-equity ratio is effectively zero, showcasing a strong capital structure with no debt burden. However, slight declines in stockholders' equity over the years may warrant attention.

Cash Flow

BioGaia AB has shown stable cash flow management with a free cash flow of SEK 359.07 million for 2024. The operating cash flow to net income ratio of 1.06 reflects good cash generation relative to earnings. However, a decrease in free cash flow growth rate from previous years suggests potential operational cash constraints.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.44B	1.42B	1.30B	1.10B	785.11M	747.08M
Gross Profit	1.04B	1.03B	950.19M	801.93M	582.95M	546.92M
EBITDA	457.51M	539.44M	494.92M	476.89M	276.86M	248.84M
Net Income	286.63M	351.39M	365.35M	373.77M	196.27M	179.73M
Balance Sheet
Total Assets	1.43B	2.03B	2.33B	2.21B	2.13B	1.91B
Cash, Cash Equivalents and Short-Term Investments	622.34M	1.22B	1.54B	1.49B	1.48B	1.47B
Total Debt	0.00	7.10M	8.80M	20.09M	10.40M	8.90M
Total Liabilities	277.75M	310.07M	302.85M	241.55M	250.69M	167.04M
Stockholders Equity	1.15B	1.72B	2.03B	1.97B	1.88B	1.75B
Cash Flow
Free Cash Flow	310.06M	359.06M	377.25M	301.03M	215.50M	205.18M
Operating Cash Flow	316.16M	373.22M	425.96M	318.94M	221.88M	221.26M
Investing Cash Flow	-6.02M	-14.07M	-50.94M	-18.14M	-126.97M	-16.07M
Financing Cash Flow	-689.88M	-689.72M	-308.42M	-313.59M	-81.85M	1.05B

BioGaia AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 105.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOG.B, the sentiment is Neutral. The current price of 105.2 is below the 20-day moving average (MA) of 106.48, above the 50-day MA of 104.52, and above the 200-day MA of 104.71, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 47.03 is Neutral, neither overbought nor oversold. The STOCH value of 34.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:BIOG.B.

BioGaia AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BIOG.B	71 Outperform	kr10.77B	36.95	22.26%	1.86%	7.88%	-6.35%
SECARE	63 Neutral	€5.39B	80.60	0.88%	0.62%	6.65%	1.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ORX	47 Neutral	kr1.29B	―	―	―	-8.79%	-91.09%
ALZCUR	47 Neutral	kr272.35M	―	-161.07%	―	―	22.73%
NANEXA	41 Neutral	€305.97M	―	-34.87%	―	-38.56%	69.37%
ENZY	38 Underperform	kr481.83M	―	―	―	11.87%	26.50%

BioGaia AB Corporate Events

BioGaia AB Announces Leadership Changes at Upcoming Extraordinary General Meeting

BioGaia AB has announced an Extraordinary General Meeting (EGM) scheduled for August 22, 2025, to address significant changes in its board leadership. The meeting will see the resignation of Peter Rothschild from the Board and the proposal to elect Mauricio Graber as the new Chairman. Graber brings extensive experience from the food ingredients and health sectors, potentially strengthening BioGaia’s strategic direction and market positioning.

BioGaia AB Reports Mixed Financial Results and Strategic Expansion

BioGaia AB reported a modest increase in net sales for the first half of 2025, with significant growth in the Adult Health segment. However, operating profit and profit after tax both saw declines, attributed to increased operating expenses. The company is expanding its global presence with direct sales in the Netherlands and has launched a new subsidiary, BioGaia New Sciences AB, to advance microbiome research.

BioGaia Expands into Skin Health with New Subsidiary

BioGaia AB has launched a new subsidiary, BioGaia New Sciences AB, to advance microbiome research beyond its core areas, focusing initially on skin health. This move aligns with the growing skin microbiome market, projected to reach USD 2.86 billion by 2032, and reflects BioGaia’s strategy to expand its science-backed product offerings in response to increasing consumer demand for microbiome-specific skincare solutions.

BioGaia AB Forms Nomination Committee for 2026 AGM

BioGaia AB has announced the formation of its Nomination Committee for the 2026 Annual General Meeting, based on the ownership structure as of June 30, 2025. The committee includes representatives from major shareholders and the Chairman of the Board, Peter Rothschild, reflecting the company’s structured governance approach. This announcement underscores BioGaia’s commitment to transparent and organized shareholder engagement, potentially impacting its strategic direction and stakeholder relations.